Drug
Deflazacort
Deflazacort: highest development phase Approved, developed by PTC Therapeutics. 8 trial records tracked on RxWires.
- Highest phase
- Approved
- Developer
- PTC Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| EMFLAZA | Approved | |
| Deflazacort NCT03642145 | Phase 3 | Duchenne Muscular Dystrophy |
| Deflazacort NCT03783923 | Phase 3 | Limb-Girdle Muscular Dystrophy |
| Deflazacort NCT02295748 | Phase 1 | Duchenne Muscular Dystrophy |
| Deflazacort NCT02286609 | Phase 1 | Hepatic Impairment |
| Deflazacort NCT02485431 | Phase 1 | Healthy Volunteers |
| Deflazacort NCT02251600 | Phase 1 | Duchenne Muscular Dystrophy |
| Deflazacort NCT02286622 | Phase 1 | Renal Impairment |
Latest
- Exclusivity ends 2026-06-07 (application 208685)
Follow Deflazacort on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.